GSK

1,455.5

+2.39%↑

HLN.UK

392.3

+1.37%↑

INDV

742

+1.71%↑

GSK

1,455.5

+2.39%↑

HLN.UK

392.3

+1.37%↑

INDV

742

+1.71%↑

GSK

1,455.5

+2.39%↑

HLN.UK

392.3

+1.37%↑

INDV

742

+1.71%↑

GSK

1,455.5

+2.39%↑

HLN.UK

392.3

+1.37%↑

INDV

742

+1.71%↑

GSK

1,455.5

+2.39%↑

HLN.UK

392.3

+1.37%↑

INDV

742

+1.71%↑

Search

AstraZeneca PLC

Abierto

SectorSalud

11,378 2.43

Resumen

Variación precio

24h

Actual

Mínimo

11026

Máximo

11438

Métricas clave

By Trading Economics

Ingresos

237M

1.7B

Ventas

1.3B

15B

P/B

Media del Sector

32.661

63.778

BPA

2.09

Rentabilidad por dividendo

2.18

Margen de beneficio

11.188

Empleados

94,300

EBITDA

-235M

4.4B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+21.44% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.18%

2.39%

Próximas Ganancias

29 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

2.8B

179B

Apertura anterior

11375.57

Cierre anterior

11378

Noticias sobre sentimiento de mercado

By Acuity

44%

56%

161 / 386 Clasificación en Healthcare

AstraZeneca PLC Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

24 mar 2025, 03:15 UTC

Principales Movimientos del Mercado

Harbour BioMed Shares Soar on News of AstraZeneca Collaboration

17 mar 2025, 07:42 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio

6 feb 2025, 11:07 UTC

Ganancias

AstraZeneca Expects Revenue, Earnings Growth Despite Sales Drop in China -- Update

31 mar 2025, 09:31 UTC

Acciones populares

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

17 mar 2025, 14:43 UTC

Charlas de Mercado

AstraZeneca's Latest Rare-Disease Drug Results Slightly Disappoint, Barclays Says -- Market Talk

17 mar 2025, 13:55 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

AstraZeneca's EsoBiotec Deal Seen as Logical -- Market Talk

17 mar 2025, 07:04 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca: Transaction Doesn't Affect Fincl Guidance for 2025.

17 mar 2025, 07:03 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca: Acquisition Expected to Close in 2Q 2025

17 mar 2025, 07:03 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca to Pay Up to $575M Upon Development, Regulatory Milestones Being Met

17 mar 2025, 07:01 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca to Make Initial Payment of $425M on Deal Closing

17 mar 2025, 07:01 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca Buying EsoBiotec for up to $1B

17 mar 2025, 07:01 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca to Buy EsoBiotec to Advance Cell Therapy Ambition

17 mar 2025, 07:00 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca to Buy EsoBiotec

28 feb 2025, 12:00 UTC

Principales Noticias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26 feb 2025, 14:59 UTC

Charlas de Mercado

AstraZeneca's Breast-Cancer Drug Results Seen as Positive Surprise -- Market Talk

26 feb 2025, 08:04 UTC

Charlas de Mercado
Ganancias

AstraZeneca's Cancer Drug Pipeline Could Fuel $80 Billion Sales Target -- Market Talk

20 feb 2025, 11:34 UTC

Adquisiciones, fusiones, absorciones

FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN

20 feb 2025, 11:34 UTC

Adquisiciones, fusiones, absorciones

FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN

20 feb 2025, 11:33 UTC

Adquisiciones, fusiones, absorciones

FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN

20 feb 2025, 11:33 UTC

Adquisiciones, fusiones, absorciones

FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN

20 feb 2025, 11:31 UTC

Adquisiciones, fusiones, absorciones

FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN

20 feb 2025, 11:30 UTC

Adquisiciones, fusiones, absorciones

FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M

13 feb 2025, 10:49 UTC

Charlas de Mercado
Ganancias

AstraZeneca Stands Out With Catalyst-Rich, Diversified Pipeline -- Market Talk

7 feb 2025, 10:30 UTC

Principales Noticias

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 feb 2025, 15:18 UTC

Charlas de Mercado

U.K. Health System Needs to Improve Investment Environment, AstraZeneca CEO Says -- Market Talk

6 feb 2025, 13:24 UTC

Charlas de Mercado

AstraZeneca's Increased R&D Spend Is a Positive -- Market Talk

6 feb 2025, 12:01 UTC

Ganancias

Global Stocks in Spotlight: BYD, Kering, Maersk -- WSJ

6 feb 2025, 11:22 UTC

Charlas de Mercado
Ganancias

AstraZeneca's Sales Beat, Pipeline Outshines Margin Miss -- Market Talk

6 feb 2025, 11:18 UTC

Charlas de Mercado
Ganancias

AstraZeneca's Outlook Makes Midterm Target Look Achievable -- Market Talk

6 feb 2025, 11:02 UTC

Charlas de Mercado
Ganancias

AstraZeneca's China Woes Seem Manageable -- Market Talk

Comparación entre iguales

Cambio de precio

AstraZeneca PLC Esperado

Precio Objetivo

By TipRanks

21.44% repunte

Estimación a 12 meses

Media 13,802.5 GBX  21.44%

Máximo 19,000 GBX

Mínimo 10,900 GBX

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AstraZeneca PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

14 ratings

10

Comprar

4

Mantener

0

Vender

Sentimiento

By Acuity

161 / 386 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.